Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anvumetostat in MTAP-deleted Thoracic Tumors
NCT06333951Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- Sep 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 1, open-label trial of anvumetostat in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Amgen. Primary endpoints: Number of Participants Experiencing Dose Limiting Toxicities at 21 days, Number of Participants Experiencing Treatment Emergent Adverse Events at 3 years and 1 more. Started Sep 2024; status: active, not recruiting.
02
Drugs
anvumetostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06333951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06333951.